Blogs

Fines for advertising cannabis and other prescription medicines

15 Dec 2023

Karen Stephens

by Karen Stephens

Medical Cannabis — Ai edit

Multiple fines for unlawful advertising of medicinal cannabis and other prescription medicines have been issued this year by the Therapeutic Goods Administration (TGA). The fines include $132,000, $742,500 and $82,500 for companies, and $6,600, $13,320 and $9,900 for individuals. In October 2023, in Federal Court proceedings, the TGA obtained a combined $5 million penalty against a company and a Director for unlawfully advertising nicotine vaping products.

It is illegal to advertise prescription-only medicines (e.g. medicinal cannabis) to Australian consumers, under the Therapeutic Goods Act 1989. The restriction relates to concerns that advertising prescription-only medicines directly to consumers undermines the doctor-patient relationship and may create an inappropriate demand for medicines which may not be right for the individual.

A doctor who is authorised to prescribe medicinal cannabis may promote this to the medical and pharmaceutical professions but not to the public. By way of example, websites and social media must not name medicinal cannabis, and patients must not be given the option to select a medicinal cannabis appointment from an online booking system.

The TGA’s compliance priorities for 2023-24 include the deterrence and disruption of unlawful advertising of nicotine vaping products, medicinal cannabis, psilocybin and MDMA.

 

More information:

 

This blog contains general information only. We recommend you contact your medical defence organisation or insurer when you require specific advice in relation to medico-legal matters.

 

Library

Doctors Let's Talk: Get Yourself A Fricking GP

Get yourself a fricking GP stat! is a conversation with Dr Lam, 2019 RACGP National General Practitioner of the Year, rural GP and GP Anesthetics trainee, that explores the importance of finding your own GP as a Junior Doctor.

Podcasts

25 Oct 2022

Systematic efforts to reduce harms due to prescribed opioids – webinar recording

Efforts are underway across the healthcare system to reduce harms caused by pharmaceutical opioids. This 43-min recording of a live webinar, delivered 11 March 2021, is an opportunity for prescribers to check, and potentially improve, their contribution to these endeavours. Hear from an expert panel about recent opioid reforms by the Therapeutic Goods Administration and changes to the Pharmaceutical Benefits Scheme. 

Diplomacy in a hierarchy: tips for approaching a difficult conversation

Have you found yourself wondering how to broach a tough topic of conversation? It can be challenging to effectively navigate a disagreement with a co-worker, especially if they're 'above' you; however, it's vital for positive team dynamics and safe patient care. In this recording of a live webinar you'll have the opportunity to learn from colleagues' experiences around difficult discussions and hear from a diverse panel moderated by Dr Kiely Kim (medico-legal adviser and general practitioner). Recorded live on 2 September 2020.